Particle.news
Download on the App Store

IMSS Strengthens Kawasaki Disease Diagnosis and Treatment Nationwide

Treatment within 10 days using intravenous immunoglobulin plus aspirin sharply lowers the risk of coronary damage.

Overview

  • Marking World Kawasaki Disease Day, IMSS announced reinforced detection, specialized care and follow-up across 195 second-level and 34 third-level units equipped with labs, echocardiography and pediatric and cardiology specialists.
  • Parents and caregivers are urged to seek care for fever lasting more than five days along with signs such as rash, red cracked lips, strawberry tongue, red eyes without discharge, swollen neck nodes and swelling or peeling of hands and feet.
  • Clinicians diagnose the illness based on clinical criteria because no specific test exists, and delays beyond the first 10 days raise the chance of cardiac complications to an estimated 25 percent.
  • IMSS reports that intravenous immunoglobulin is available at second- and third-level units with adjunct aspirin to reduce thrombosis risk, supported by hemogram, urinalysis and echocardiogram to assess coronary involvement.
  • Mexico lacks an official registry, and IMSS estimates roughly 240 cases annually, mostly in children aged two to three, with limited rural access and low first-level familiarity contributing to late diagnoses and risks such as coronary aneurysms or myocardial infarction.